Development of a potent small‐molecule degrader against oncogenic BRAF(V600E) protein that evades paradoxical MAPK activation

BRAF mutations are frequently observed in melanoma and hairy‐cell leukemia. Currently approved rapidly accelerated fibrosarcoma (RAF) kinase inhibitors targeting oncogenic BRAF V600 mutations have shown remarkable efficacy in the clinic, but their therapeutic benefits are occasionally hampered by ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohoka, Nobumichi, Suzuki, Masanori, Uchida, Takuya, Tsukumo, Yoshinori, Yoshida, Masayuki, Inoue, Takao, Ohki, Hitoshi, Naito, Mikihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357609/
https://www.ncbi.nlm.nih.gov/pubmed/35579105
http://dx.doi.org/10.1111/cas.15401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357609/
https://www.ncbi.nlm.nih.gov/pubmed/35579105
http://dx.doi.org/10.1111/cas.15401

Ejemplares similares